QIAGEN N.V.QGEN
Recorded

QIAGEN N.V. 2026 Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Robbie BambergerAnalyst

Okay. Good to go? Okay.

Robbie BambergerAnalyst

All right. Good afternoon, everyone. I'm Robert Bamberger, senior research analyst covering life sciences and diagnostics here at Baird. We're pleased to welcome Qiagen this afternoon. Especially pleased to welcome Jonathan Pratt, who became Qiagen's CEO on September 1, so we're catching him right at the 2-week mark. We also have Roland Sackers, Qiagen CFO, and Domenica from IR with us as well. Thank you guys for all making the trip. John, just before we get into the business, I wanted to start with you. You stepped into the CEO seat September 1, so we're catching you 2 weeks in. What was it about Qiagen that made you want this job? In your conversation with the supervisory board, what were they telling you they wanted most for the next CEO of Qiagen?

Jonathan PrattCEO

Yeah. Thank you again. Good to be here. I guess I knew Qiagen. I've been involved in the space through Pall and through Beckman Coulter and through Waters for a long time. I knew Qiagen from an undergrad perspective.

Jonathan PrattCEO

Okay. Almost every customer I touched was the blue boxes, so to speak.

Jonathan PrattCEO

I knew the brand. Did a bit of research on the brand and, in terms of the customer intimacy and the quality of the people employed in Qiagen, it was a pretty exciting place to come. So I was intrigued to join. It took a long time because I was in the business of selling Filtration Group to Parker Hannifin, so there was a long transition period.

Jonathan PrattCEO

Yep. It gave me chance to understand the company a lot.

Jonathan PrattCEO

Supervisory board, they really felt that they obviously wanted the industry experience, allied experience. In no particular order, they were pleased that I'd lived and worked in the U.S. and U.K. As you can tell from my accent, I was not exactly born in Brooklyn. That fitted well. They wanted somebody that could bring some simplicity, shall we say, to some complexity. Strategic focus, very much execution driven. My experience with Waters and others was an execution kind of game in many, many ways. All the things aligned well there. Somebody that would fit with the culture.

Jonathan PrattCEO

Yep. Lots and lots of things.

Robbie BambergerAnalyst

You spent most of your career in businesses that looked a lot like Qiagen. President of Beckman Coulter Life Sciences inside Danaher, senior roles at Pall, and then the Waters Division at Waters Corp. What are the maybe one or two things from those seats that you think could travel best to Qiagen?

Jonathan PrattCEO

I think the two things I'd highlight is R&D effectiveness, choice, prioritization, link to strategy. They're very much part of the Waters and Pall journey. The other one is, I would say commercial execution in all its forms. Beckman and Waters in particular, we benefited from upgrading kind of the commercial capabilities. The depth of technical capability is always there, but commercial execution in all its forms is something I would say that was important.

Robbie BambergerAnalyst

How are you spending your first 90 days, and when should investors expect to hear your view on the strategy and medium-term framework for Qiagen?

Jonathan PrattCEO

Yeah. Obviously, listen, learn phase, right? Diving deep. Had quite a bit of time pre-appointment to dive deep, but building on that, getting to know the enterprise, the people, the places and traveling to all of our facilities. Really trying to understand how we win in each of our growth pillars, and what the midterm outlook is of that, and frankly, where we probably should double down on and where we should manage differently. So, classic onboarding process, really.

Robbie BambergerAnalyst

Yep. Roland, I'll include you on this one. The strategic review of the company, framed it as a continuous process with three paths, continue organically, strategic partner, or a financially driven partner. Can you maybe walk through all of those three options from your seat now?

Roland SackersCFO

I don't think that I want to distinguish between the different parts of it- Yep I do think it's very fair to say, and John, I think, was alluding to that right now, there's clearly a path A and there's a plan B.

Roland SackersCFO

Again, one thing is also very clear, we want to have, rather, a clear direction rather sooner than later. It's nothing what we want to decide end of this year, whatever. Of course, we need a clear path going forward, and I think we are all very much committed to that and delivering on that. Again, right now, by definition, I can't give you much more update other than that we're working hard to get, rather in weeks than in months, to a clear decision.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

More recent earnings calls

View earnings calendar